Healio

Nerandomilast lowers FVC decline in progressive pulmonary fibrosis at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...
Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Two differing nerandomilast doses were assessed against ...
The American Journal of Managed Care

Nerandomilast Slows Lung Function Decline in Patients With IPF

Nerandomilast significantly slowed lung function decline in patients with IPF, with the 18 mg dose showing a 68.8 mL FVC decline reduction compared with placebo. The trial included 1177 patients, 78% ...
Monthly Prescribing Reference

Study Finds Nerandomilast Improves Lung Function in Patients With Progressive Pulmonary Fibrosis

Findings showed treatment with nerandomilast led to a significant improvement in lung function compared with placebo. Topline data were announced from a phase 3 trial evaluating nerandomilast, an oral ...
Yahoo Finance

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function. 1 Approval is based on results from two ...
Yahoo Finance

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...
PharmiWeb

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 ...
PMLiVE

Boehringer’s nerandomilast shows promise in phase 3 pulmonary fibrosis study

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational nerandomilast in progressive pulmonary fibrosis (PPF). The phase 3 FIBRONEER-ILD trial ...
Monthly Prescribing Reference

Nerandomilast Shows Promise in Idiopathic Pulmonary Fibrosis Trial

A New Drug Application will be submitted to the Food and Drug Administration based on these results. Top-line results were announced from a phase 3 trial evaluating nerandomilast an oral, ...
PMLiVE

Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials

Boehringer Ingelheim (BI) has unveiled results from two late-stage studies of nerandomilast in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The phase 3 FIBRONEER-IPF ...
Drug Target Review

Why PDE4B matters in the search for better IPF and PPF therapies

Could targeting a enzyme play a role in slowing lung fibrosis? Boehringer Ingelheim’s research into PDE4B is offering ...